Phototherapy of Sclerosing Skin Diseases

Ghoreschi, Kamran; Röcken, Martin

doi:10.1159/000065857

Cited by 6 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UVA1 phototherapy is of particular significance in the treatment of sclerosing skin diseases [72][73][74][75]. The effectiveness of UVA1 in localized scleroderma has been confirmed by several studies [72,[76][77][78][79][80][81].…”

Section: Connective Tissue Disorders Marked By Sclerosismentioning

confidence: 88%

S1‐Guidelines on UV phototherapy and photochemotherapy

Herzinger

Berneburg

Ghoreschi

et al. 2016

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

Known in part since antiquity, the salutary effects of sunlight again garnered increasing attention in the second half of the 19(th) century. The development of a device for ultraviolet irradiation of cutaneous tuberculosis by Finnsen at the onset of the twentieth century truly marked the beginning of modern phototherapy. In dermatology, treatment methods almost exclusively use wavelengths below the visible light range (ultraviolet light). Since the early 1970s, increasingly powerful artificial light sources have become available for UVB and UVA therapy as well as the combination of UVA and photosensitizers (photochemotherapy). High structural and procedural quality standards are an essential prerequisite for the implementation of effective as well as safe phototherapy. The following guidelines outline the current consensus of leading experts in the field of phototherapy with respect to indications, contraindications, and side effects of various treatment options available. Particular focus is also on adequate UV doses at the beginning and over the further course of treatment as well as on management of side effects.

show abstract

Section: Connective Tissue Disorders Marked By Sclerosismentioning

confidence: 88%

S1‐Guidelines on UV phototherapy and photochemotherapy

Herzinger

Berneburg

Ghoreschi

et al. 2016

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

show abstract

“…Einen besonderen Stellenwert hat die UV‐A1‐Phototherapie in der Behandlung sklerosierender Hautkrankheiten ). Die Wirksamkeit von UV‐A1 bei der zirkumskripten Sklerodermie konnte in mehreren Studien bestätigt werden.…”

Section: Uv‐a1‐phototherapieunclassified

S1‐Leitlinie zur UV‐Phototherapie und Photochemotherapie

Herzinger

Berneburg

Ghoreschi

et al. 2016

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

Die heilsame Wirkung des Sonnenlichts war teilweise schon im Altertum bekannt und fand in der zweiten Hälfte des 19. Jahrhunderts wieder zunehmend Beachtung. Den Beginn der modernen Phototherapien markiert die Entwicklung einer Apparatur zur ultravioletten Bestrahlung der Hauttuberkulose durch Finnsen zu Beginn des zwanzigsten Jahrhunderts. Zur Therapie von Hauterkrankungen finden beinahe ausschließlich die spektralen Bereiche unterhalb des sichtbaren Lichtes (ultraviolett) Anwendung. Seit den 1970er Jahren stehen zunehmend leistungsfähige künstliche Strahlenquellen bereit für die Therapie mit UVB, UVA und die Kombination von UVA mit Photosensibilisatoren (Photochemotherapie). Hohe strukturelle und prozedurale Qualitätsstandards sind unabdingbare Voraussetzung für die Durchführung einer gleichermaßen wirkungsvollen wie auch sicheren Phototherapie. Die Leitlinie formuliert den aktuellen Konsens führender Experten auf dem Gebiet der Phototherapie in Bezug auf die Indikationen für die jeweiligen Therapieverfahren, deren Gegenanzeigen und Nebenwirkungen und insbesondere für die Wahl der korrekten Dosis zu Beginn und im Verlauf einer Therapie sowie das Management von Nebenwirkungen.

show abstract

“…Systemic sclerosis is a chronic connective tissue inflammatory disease responsible for severe facial skin alterations that cause limitations and difficulties in different areas of daily life, as well as disfiguring malformations and changes in appearance [5]. Additionally, to date, there are no effective local therapies that can guarantee a satisfactory result neither from an esthetic nor from a functional point of view [6–17]. To date, the only therapeutic strategies that achieved results consisted in autologous fat grafting [33, 34].…”

Section: Discussionmentioning

confidence: 99%

“…Although there are no specific drugs for treatment, many strategies have been tried (pharmacological or non-pharmacological treatment) [3–6] such as UVA phototherapy [7–9], corticosteroids and immunomodulators [10], topical calcitriol [11–13], and etretinate [14–17], but none of these has given a good and long-lasting result.…”

Section: Introductionmentioning

confidence: 99%

Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

et al. 2019

View full text Add to dashboard Cite

BackgroundSystemic sclerosis is a systemic connective tissue disease characterized by endothelium damage, fibrosis, and subsequent atrophy of the skin. Perioral fibrosis produces a characteristic microstomia together with microcheilia, both of which cause severe difficulties and affects patients’ daily life, such as eating and oral hygiene. Since there are no effective and specific therapies, we have aimed at evaluating the response to filler injections of hyaluronic acid together with platelet-rich plasma.MethodsTen female patients aged between 18 and 70 were included in this study. Each patient was treated with three filler injections of hyaluronic acid and platelet-rich plasma at an interval of 15 to 20 days. Follow-up check-ups were recorded 1, 3, and 24 months after the end of the treatment. During the therapy and the subsequent follow-up, we evaluated the mouth’s opening, freedom of movement of the lips, and skin elasticity.ResultsAfter the treatment, patients had achieved good results already after the first injection and the improvement was maintained in the following months, up to 2 years. In particular, 8 (80%) patients showed a greater mouth’s opening and increased upper lip’s thickness during 1-month follow-up and maintained these results after 2 years (maximum mouth’s opening T0 47.61; T3 49.23; T4 48.60 p < 0.0001. Upper lip’s thickness T0 4.20; T3 4.75; T4 4.45 p < 0.0001). Moreover, distance between upper and lower incisors (T0 27.05; T3 29.03; T4 28.14 p < 0.0001), inter-commissural distance (T0 49.12; T3 51.44; T4 50.31: p < 0.0001), and lower lip’s thickness (T0 3.80; T3 4.85, 5.10; T4 4.25; p < 0.0001) were increased in all of patients in 1-month follow-up, keeping these benefits after 24 months and having a significant increase of skin elasticity 1 month after the end of therapy.ConclusionsOur study demonstrates that filler injections of hyaluronic acid and platelet-rich plasma represent an efficient local therapeutic alternative for patients affected by scleroderma. The treatment has significantly improved patients’ quality of living.

show abstract

Phototherapy of Sclerosing Skin Diseases

Cited by 6 publications

References 24 publications

S1‐Guidelines on UV phototherapy and photochemotherapy

S1‐Guidelines on UV phototherapy and photochemotherapy

S1‐Leitlinie zur UV‐Phototherapie und Photochemotherapie

Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

Contact Info

Product

Resources

About